ING Groep NV lessened its stake in Incyte Co. (NASDAQ:INCY) by 54.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,166 shares of the biopharmaceutical company’s stock after selling 2,554 shares during the quarter. ING Groep NV’s holdings in Incyte were worth $205,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds also recently bought and sold shares of INCY. Ark Investment Management LLC increased its position in Incyte by 171.2% in the 2nd quarter. Ark Investment Management LLC now owns 3,911 shares of the biopharmaceutical company’s stock valued at $492,000 after acquiring an additional 2,469 shares in the last quarter. Mutual of America Capital Management LLC increased its position in Incyte by 2.7% in the 3rd quarter. Mutual of America Capital Management LLC now owns 21,398 shares of the biopharmaceutical company’s stock valued at $2,498,000 after acquiring an additional 570 shares in the last quarter. Oakbrook Investments LLC boosted its stake in shares of Incyte by 26.3% in the 3rd quarter. Oakbrook Investments LLC now owns 16,080 shares of the biopharmaceutical company’s stock valued at $1,877,000 after purchasing an additional 3,350 shares during the last quarter. APG Asset Management N.V. boosted its stake in shares of Incyte by 15.7% in the 3rd quarter. APG Asset Management N.V. now owns 55,956 shares of the biopharmaceutical company’s stock valued at $6,532,000 after purchasing an additional 7,600 shares during the last quarter. Finally, Fox Run Management L.L.C. bought a new position in shares of Incyte in the 3rd quarter valued at about $630,000. Hedge funds and other institutional investors own 89.43% of the company’s stock.
Incyte Co. (NASDAQ:INCY) opened at $84.71 on Thursday. Incyte Co. has a one year low of $80.85 and a one year high of $153.15. The company has a quick ratio of 3.99, a current ratio of 4.01 and a debt-to-equity ratio of 0.01.
Incyte (NASDAQ:INCY) last released its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.54. Incyte had a negative net margin of 20.38% and a negative return on equity of 11.85%. The business had revenue of $444.20 million for the quarter, compared to analyst estimates of $435.23 million. During the same quarter last year, the firm earned $0.05 EPS. Incyte’s quarterly revenue was up 36.0% compared to the same quarter last year. equities research analysts expect that Incyte Co. will post -0.18 earnings per share for the current year.
In other Incyte news, EVP Vijay K. Iyengar sold 5,000 shares of Incyte stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $97.26, for a total value of $486,300.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider David W. Gryska sold 6,760 shares of Incyte stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $98.87, for a total transaction of $668,361.20. Following the completion of the transaction, the insider now directly owns 20,752 shares in the company, valued at approximately $2,051,750.24. The disclosure for this sale can be found here. Insiders have sold a total of 12,456 shares of company stock worth $1,222,876 in the last three months. 17.70% of the stock is owned by insiders.
Several research analysts have recently issued reports on INCY shares. Deutsche Bank started coverage on shares of Incyte in a research note on Tuesday, December 12th. They issued a “hold” rating and a $106.00 target price on the stock. Oppenheimer reaffirmed a “hold” rating and issued a $110.00 target price (down previously from $120.00) on shares of Incyte in a research note on Monday, January 22nd. Zacks Investment Research lowered shares of Incyte from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. BMO Capital Markets reduced their target price on shares of Incyte from $163.00 to $162.00 and set an “outperform” rating on the stock in a research note on Thursday, October 26th. Finally, Citigroup reaffirmed a “market perform” rating and issued a $120.00 target price (down previously from $135.00) on shares of Incyte in a research note on Tuesday, January 2nd. Three analysts have rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $142.94.
ILLEGAL ACTIVITY NOTICE: “ING Groep NV Lowers Holdings in Incyte Co. (INCY)” was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/02/22/ing-groep-nv-lowers-holdings-in-incyte-co-incy.html.
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCY).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.